• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[利妥昔单抗联合剂量密集、剂量冲击性每周化疗方案治疗CD20阳性B细胞非霍奇金淋巴瘤患者的结果]

[Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma].

作者信息

Uzuka Yoshirou, Saitou Yoshiko, Saitou Kei, Suzuki Souzou, Yamaguchi Masato

机构信息

Sendai Blood Disease Center.

出版信息

Gan To Kagaku Ryoho. 2007 Jul;34(7):1085-90.

PMID:17637545
Abstract

Excellent results were reported for dose-dense and dose-intense weekly combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide and additional ara-C) (CHOEA-7) and with rituximab (RCHOEA-7), for patients with CD 20-positive non-Hodgkin's lymphoma.

摘要

对于CD 20阳性的非霍奇金淋巴瘤患者，剂量密集和剂量强度的每周联合化疗（环磷酰胺、多柔比星、长春新碱、依托泊苷和额外的阿糖胞苷）（CHOEA-7）以及联合利妥昔单抗（RCHOEA-7）均报告了出色的疗效。

相似文献

1
[Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma].[利妥昔单抗联合剂量密集、剂量冲击性每周化疗方案治疗CD20阳性B细胞非霍奇金淋巴瘤患者的结果]
Gan To Kagaku Ryoho. 2007 Jul;34(7):1085-90.
2
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).法国成人淋巴瘤研究组（GELA）进行的一项随机2期试验：两种一线利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松加硼替佐米方案治疗B细胞淋巴瘤患者的疗效与毒性
Cancer. 2009 Oct 1;115(19):4540-6. doi: 10.1002/cncr.24518.
3
Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.增加化疗剂量密度和强度：非小细胞肺癌和非霍奇金淋巴瘤的I期试验
Oncologist. 2005 Feb;10(2):138-49. doi: 10.1634/theoncologist.10-2-138.
4
Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.利妥昔单抗联合 CHOP 化疗治疗 B 细胞非霍奇金淋巴瘤的药代动力学研究。
Fundam Clin Pharmacol. 2009 Oct;23(5):601-8. doi: 10.1111/j.1472-8206.2009.00714.x. Epub 2009 Jul 29.
5
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.大剂量阿糖胞苷联合放疗并进行自体移植挽救治疗R-CHOP方案敏感的套细胞淋巴瘤患者。
Br J Haematol. 2009 Feb;144(4):524-30. doi: 10.1111/j.1365-2141.2008.07498.x. Epub 2008 Nov 26.
6
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.人源化抗CD22抗体依帕珠单抗联合利妥昔单抗治疗难治性或复发性非霍奇金淋巴瘤的多中心II期免疫治疗试验。
J Clin Oncol. 2006 Aug 20;24(24):3880-6. doi: 10.1200/JCO.2006.05.6291. Epub 2006 Jul 24.
7
Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.非聚乙二醇化脂质体阿霉素治疗B细胞非霍奇金淋巴瘤：现状
Expert Rev Anticancer Ther. 2009 Mar;9(3):357-63. doi: 10.1586/14737140.9.3.357.
8
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.复发惰性和侵袭性非霍奇金淋巴瘤患者中，Toll样受体9激动剂PF-3512676联合利妥昔单抗及利妥昔单抗治疗后的I期试验
Clin Cancer Res. 2007 Oct 15;13(20):6168-74. doi: 10.1158/1078-0432.CCR-07-0815.
9
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.脂质体包裹的阿霉素联合环磷酰胺、长春新碱、泼尼松和利妥昔单抗用于患有淋巴瘤且合并心脏疾病或曾接受蒽环类药物预处理的患者。
Hematol Oncol. 2007 Dec;25(4):198-203. doi: 10.1002/hon.827.
10
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.苯达莫司汀联合利妥昔单抗治疗复发惰性B细胞和套细胞非霍奇金淋巴瘤的II期多中心研究
J Clin Oncol. 2008 Sep 20;26(27):4473-9. doi: 10.1200/JCO.2008.17.0001. Epub 2008 Jul 14.

引用本文的文献

1
Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method.使用相位跟踪法对血液系统恶性肿瘤患者蒽环类药物诱导的心脏毒性进行无创早期检测。
Cancer Med. 2016 Sep;5(9):2276-85. doi: 10.1002/cam4.813. Epub 2016 Aug 3.